TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31972580

Group type: EXPERIMENTAL
Intervention: Compression therapy (71% of patients received this intervention)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Assessment tools used (92% of files indicated use)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Assessment of smoking, body mass index, and anemia
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Use of handheld Dopplers (available in 66% of facilities)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Formal wound care training for personnel (61% indicated no training)
Number of subjects: 160
Study: 30218229

Group type: COMPARATOR
Intervention: Zinc oxide eugenol control cement (ZOE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer cement (GIC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: MTA (Mineral Trioxide Aggregate)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Portland cement
Number of subjects: 50
Study: 29719839

Group type: EXPERIMENTAL
Intervention: 5 liters of irrigation
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 10 liters of irrigation
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 20 liters of irrigation
Number of subjects: 204

Group type: COMPARATOR
Intervention: Overall mortality rate
Number of subjects: 204
Study: 26294138

Group type: EXPERIMENTAL
Intervention: Triphasic waves (TWs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No triphasic waves (non-TWs)
Number of subjects: 20
Study: 24481723

Group type: EXPERIMENTAL
Intervention: Intramyocardial bone marrow cell injection
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22315948

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily
Number of subjects: 600

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 600
Study: 19890125

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2203

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 2203
Study: 17728426

Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg/day for the first 4 weeks, then 30 mg/day for the following 4 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Aripiprazole (for female patients with menstrual disturbances)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (for female patients with menstrual disturbances)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 56
Study: 15316907

Group type: EXPERIMENTAL
Intervention: Behavior change interventions in cancer screening research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer screening strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer screening behaviors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized designs
Number of subjects: 0
Study: 11936356

Group type: EXPERIMENTAL
Intervention: Rifampicin-bonded Dacron grafts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard grafts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study group (rifampicin-bonded Dacron grafts)
Number of subjects: 0
Study: 9604598

Group type: EXPERIMENTAL
Intervention: Serum retinol levels in infants and adults; specific levels not detailed; analysis of cord blood, infantile and adult levels of retinol.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum retinol levels in women (pregnant or non-pregnant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cut-off level for deficiency
Number of subjects: 0
Study: 7506675

Group type: EXPERIMENTAL
Intervention: rhG‐CSF
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: rhIL‐3
Number of subjects: 22
Study: 2574766

Group type: EXPERIMENTAL
Intervention: Oxpentifylline (500 mg over 4 h) after 100 ng endotoxin injection
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (100 ng endotoxin injection without oxpentifylline)
Number of subjects: 10
Study: 1183792

Group type: EXPERIMENTAL
Intervention: Low dose Heparin (Liquemin Roche) subcutaneously, 5000 units 2 hours pre-operatively and every 12 hours until the eighth post-operative day
Number of subjects: 458

Group type: COMPARATOR
Intervention: Oral anti-coagulants (Sintrom) from the second post-operative day to complete ambulation, maintaining quick test between 20 and 30%
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Low dose Heparin
Number of subjects: 458

Group type: COMPARATOR
Intervention: Oral anti-coagulants (Sintrom)
Number of subjects: 458
Study: 30915723

Group type: EXPERIMENTAL
Intervention: Supplemental calcium with or without vitamin D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D co-administration
Number of subjects: 0
Study: 28633157

Group type: EXPERIMENTAL
Intervention: Intraoperative ventilation management for patients at increased risk of PPCs
Number of subjects: 9864

Group type: COMPARATOR
Intervention: Intraoperative ventilation management for patients at low risk of PPCs
Number of subjects: 9864

Group type: EXPERIMENTAL
Intervention: Ventilatory management (Tidal Volume and PEEP)
Number of subjects: 9864
Study: 26156625

Group type: COMPARATOR
Intervention: Rosuvastatin (2.5 mg)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Pitavastatin (1 or 2 mg)
Number of subjects: 134
Study: 24511717

Group type: EXPERIMENTAL
Intervention: LED phototherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 50
Study: 21971374

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Calcitonin 200 IU
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Vitamin D 400 IU
Number of subjects: 81

Group type: COMPARATOR
Intervention: Untreated group (Control)
Number of subjects: 81
Study: 18452434

Group type: EXPERIMENTAL
Intervention: Cream containing retinol, lactose and glycolic acid applied twice daily for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 12 weeks
Number of subjects: 40
Study: 16670692

Group type: EXPERIMENTAL
Intervention: Imedeen Prime Renewal (two tablets twice daily for 6 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (two tablets twice daily for 6 months)
Number of subjects: 80
Study: 14605896

Group type: EXPERIMENTAL
Intervention: Slow cooling conditions (above 10 s to reach TC=0.5 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fast cooling conditions (below 10 s to reach TC=0.5 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: General linear model approach
Number of subjects: 10
Study: 11680668

Group type: EXPERIMENTAL
Intervention: Tinzaparin (175 IU/kg)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Tinzaparin (4,500 IU)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Control (Heparin)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg)
Number of subjects: 425
Study: 9226735

Group type: EXPERIMENTAL
Intervention: ORG 5222, 100 micrograms
Number of subjects: 3
Study: 7964961

Group type: EXPERIMENTAL
Intervention: Dexamethasone (day 1, 0.2 mg/kg i.v.; days 2 through 6, 8 mg orally)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Conventional-dose alizapride (day 1, 100 mg i.v. and 4 x 50 mg orally; days 2 through 6, 4 x 50 mg orally)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Doubling the dose of tropisetron (10 mg once daily)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study: 3597568

Group type: EXPERIMENTAL
Intervention: Family therapy intervention (approximately six sessions within 3-5 months of bereavement)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 29059139

Group type: EXPERIMENTAL
Intervention: HARRL (with lidocaine)
Number of subjects: 170

Group type: COMPARATOR
Intervention: HAJU (without lidocaine)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: HARRL
Number of subjects: 170

Group type: COMPARATOR
Intervention: HAJU
Number of subjects: 170
Study: 29122785

Group type: EXPERIMENTAL
Intervention: Naoxuekang
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Xinnaoshutong (XNST)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Xuesaitong (XST)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 25775674

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 60

Group type: COMPARATOR
Intervention: Uncoated balloon
Number of subjects: 60
Study: 23294549

Group type: EXPERIMENTAL
Intervention: DMPA-SC self-administration
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: DMPA-SC self-administration proficiency ratings
Number of subjects: 55
Study: 21422325

Group type: EXPERIMENTAL
Intervention: Video-based intervention (DVD and 2 postcard reminders)
Number of subjects: 930

Group type: COMPARATOR
Intervention: Brochures-only control
Number of subjects: 930
Study: 18327010

Group type: EXPERIMENTAL
Intervention: 30 mg IM for 6 weeks followed by 15 mg IM for 6 weeks (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30 mg IM weekly for 12 weeks (group 2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 20
Study: 16458955

Group type: EXPERIMENTAL
Intervention: Troop and Internet program to increase physical activity skills, self-efficacy, and goal-setting over 9 weeks
Number of subjects: 473

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 473
Study: 12521624

Group type: EXPERIMENTAL
Intervention: IVUS guidance
Number of subjects: 269

Group type: COMPARATOR
Intervention: ANGIO guidance
Number of subjects: 269
Study: 11044230

Group type: EXPERIMENTAL
Intervention: Pretreatment blood pressure measurements
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Post-treatment blood pressure measurements (120 minutes)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Ramipril treatment
Number of subjects: 163

Group type: COMPARATOR
Intervention: Conventional antihypertensive therapy
Number of subjects: 163
Study: 8844941

Group type: EXPERIMENTAL
Intervention: Promotion of organ donor card-signing through persuasive communication strategies
Number of subjects: 0
Study: 1735484

Group type: EXPERIMENTAL
Intervention: Parlodel SRO (5 mg/d for first 15 days, then 10 mg/d for 1 month; variable doses up to 20 mg/d for 1 year)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Parlodel (5 mg/d for first 15 days, then 10 mg/d for 1 month)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Parlodel SRO (1 year treatment)
Number of subjects: 16
Study: 6371278

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 5,000 IU
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 2,500 IU
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Heparin sodium, 5,000 IU alone
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine mesylate, 0.5 mg alone
Number of subjects: 880

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880
Study: 31206083

Group type: EXPERIMENTAL
Intervention: 5 mg of zinc sulfate daily for 14 days
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: 10 mg of zinc sulfate daily for 14 days
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: 20 mg of zinc sulfate daily for 14 days
Number of subjects: 4500

Group type: COMPARATOR
Intervention: WHO/Unicef Integrated Management of Childhood Illness standard of care
Number of subjects: 4500
Study: 28807645

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention (226 participants)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Control group (112 participants)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 338
Study: 27779461

Group type: EXPERIMENTAL
Intervention: lercanidipine/enalapril
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide/enalapril
Number of subjects: 56

Group type: COMPARATOR
Intervention: enalapril/amlodipine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 56
Study: 25007690

Group type: EXPERIMENTAL
Intervention: Epidural butorphanol 0.04 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epidural morphine 0.06 mg/kg
Number of subjects: 80
Study: 22748873

Group type: EXPERIMENTAL
Intervention: Degarelix 240 mg for 1 month followed by monthly maintenance doses of 80 or 160 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leuprolide 7.5 mg/month
Number of subjects: 0
Study: 20131032

Group type: EXPERIMENTAL
Intervention: Qianggan Capsule (QGC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Polyene phosphatidylcholine capsule (PPC)
Number of subjects: 88
Study: 17418289

Group type: EXPERIMENTAL
Intervention: Early abciximab administration (in the emergency room)
Number of subjects: 210
Study: 16271912

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg daily (n = 120)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Naproxen 750 mg daily and Lansoprazole 30 mg daily (n = 122)
Number of subjects: 224
Study: 12398965

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects (age- and gender-matched with negative treadmill exercise tests)
Number of subjects: 20
Study: 9972551

Group type: EXPERIMENTAL
Intervention: Mortality salience inductions
Number of subjects: 603

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Positive feedback about driving (Study 4)
Number of subjects: 603
Study: 7752918

Group type: EXPERIMENTAL
Intervention: Doxazosin (maximum 12 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2182169

Group type: EXPERIMENTAL
Intervention: Weekly oral pulse methotrexate
Number of subjects: 53

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 53
Study: 527341

Group type: EXPERIMENTAL
Intervention: Progestasert IUD
Number of subjects: 295

Group type: COMPARATOR
Intervention: Copper 7 IUD
Number of subjects: 295

Group type: COMPARATOR
Intervention: Comparison of Progestasert and Copper 7 IUDs
Number of subjects: 295

Group type: COMPARATOR
Intervention: Comparison of premenstrual and intermenstrual cramps
Number of subjects: 295
Study: 31014386

Group type: EXPERIMENTAL
Intervention: Retrograde inferior vena caval perfusion (RIVP) combined with selective antegrade cerebral perfusion (ACP) under moderate hypothermia
Number of subjects: 636

Group type: COMPARATOR
Intervention: Selective antegrade cerebral perfusion (ACP) under moderate hypothermia
Number of subjects: 636
Study: 28781115

Group type: EXPERIMENTAL
Intervention: Reading the screening leaflet
Number of subjects: 226

Group type: COMPARATOR
Intervention: Not reading the screening leaflet
Number of subjects: 226
Study: 27292104

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Number of subjects: 326

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 326
Study: 24613159

Group type: EXPERIMENTAL
Intervention: Infection prevention measures including chlorhexidine-alcohol skin preparation and avoidance of BITA grafts in obese diabetic women.
Number of subjects: 1001

Group type: COMPARATOR
Intervention: BITA grafting in obese diabetic women.
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: General infection prevention measures applied during CABG.
Number of subjects: 1001
Study: 22300739

Group type: EXPERIMENTAL
Intervention: Ergocalciferol 50,000 IU weekly
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 19543205

Group type: EXPERIMENTAL
Intervention: Low-GI diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-GI diet
Number of subjects: 12
Study: 17259573

Group type: EXPERIMENTAL
Intervention: DUI court
Number of subjects: 284

Group type: COMPARATOR
Intervention: Traditional criminal court
Number of subjects: 284
Study: 15242032

Group type: EXPERIMENTAL
Intervention: PEEP of 5 cmH2O
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PEEP adjusted to the patient's lower inflection point (LIP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 12404693

Group type: EXPERIMENTAL
Intervention: Nicotine (21 mg/day via transdermal patch)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (transdermal patch)
Number of subjects: 10
Study: 12669739

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8674919

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with porfimer sodium and argon‐pumped dye laser
Number of subjects: 236

Group type: COMPARATOR
Intervention: Nd:YAG laser therapy
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 236
Study: 1694421

Group type: EXPERIMENTAL
Intervention: Vancomycin (15 mg/kg over 60 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Teicoplanin (15 mg/kg over 30 min)
Number of subjects: 12
Study: 694800

Group type: EXPERIMENTAL
Intervention: Clemastine (0.05%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol (0.5%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31838924

Group type: EXPERIMENTAL
Intervention: PRGF injection once
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PRGF injection thrice
Number of subjects: 13
Study: 31298499

Group type: EXPERIMENTAL
Intervention: Palliative care intervention implemented in 20 nursing homes over a six-month period
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study: 28040235

Group type: EXPERIMENTAL
Intervention: palonosetron 0.075mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: lidocaine 20mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: saline
Number of subjects: 120
Study: 25898203

Group type: EXPERIMENTAL
Intervention: Problems on four domains (functional, somatic, mental, social)
Number of subjects: 2681

Group type: EXPERIMENTAL
Intervention: Problems on all four domains
Number of subjects: 2681

Group type: EXPERIMENTAL
Intervention: Increased number of domains with problems
Number of subjects: 2681
Study: 23689430

Group type: EXPERIMENTAL
Intervention: Maintenance vandetanib (300 mg/day orally)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Maintenance placebo
Number of subjects: 162
Study: 20467870

Group type: EXPERIMENTAL
Intervention: ePTFE/FEP-covered stents
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bare nitinol stents
Number of subjects: 80
Study: 19786221

Group type: EXPERIMENTAL
Intervention: Topical clindamycin
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 15969905

Group type: EXPERIMENTAL
Intervention: Priming of visual search by repeated target location
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Priming of visual search by repeated target color
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Briefer displays
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Color priming from missed targets
Number of subjects: 2
Study: 10573550

Group type: EXPERIMENTAL
Intervention: Oral vitamin A, 15 mg retinol equivalent (RE) with TOPV
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Oral vitamin A, 7.5 mg RE with TOPV
Number of subjects: 467

Group type: COMPARATOR
Intervention: Placebo with TOPV
Number of subjects: 467
Study: 9199118

Group type: EXPERIMENTAL
Intervention: Chronic exposure to carbon disulfide (CS2)
Number of subjects: 140
Study: 1672698

Group type: EXPERIMENTAL
Intervention: Atenolol (ATN) 100 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Propranolol (PRP) 40 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 7154707

Group type: EXPERIMENTAL
Intervention: Weekly bolus (5 mg/m2 i.v. X 4)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fractionated daily injections (0.5 mg/m2 i.v. q.12 h X 10, course to be repeated after 10‐15 days)
Number of subjects: 46
Study: 31859205

Group type: EXPERIMENTAL
Intervention: Discharge education intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 66
Study: 31383594

Group type: EXPERIMENTAL
Intervention: active cTBS
Number of subjects: 30

Group type: COMPARATOR
Intervention: sham cTBS
Number of subjects: 30
Study: 29489429

Group type: EXPERIMENTAL
Intervention: Nut consumption (two or more servings of nuts per week)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Tree nut intake
Number of subjects: 826
Study: 26833162

Group type: EXPERIMENTAL
Intervention: Lopinavir (LPV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gag amino acid substitutions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gag and protease amino acid changes
Number of subjects: 20
Study: 25174321

Group type: EXPERIMENTAL
Intervention: Computerized asthma management system (workflow-integrated, computer-based asthma scoring, guideline-compliant order sets)
Number of subjects: 788

Group type: COMPARATOR
Intervention: Standard asthma management
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Computerized asthma management system
Number of subjects: 788
Study: 21934629

Group type: EXPERIMENTAL
Intervention: Fimasartan (240 mg) with Hydrochlorothiazide (HCTZ, 25 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ, 25 mg) with Fimasartan (240 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fimasartan alone
Number of subjects: 32
Study: 18981951

Group type: EXPERIMENTAL
Intervention: 20 g of soy protein with 160 mg of total isoflavones (64 mg genistein, 63 mg daidzein, and 34 mg glycitein) for 12 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: 20 g of soy protein placebo for 12 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Comparison of pre‐post change between the groups
Number of subjects: 75
Study: 17244766

Group type: EXPERIMENTAL
Intervention: Sitagliptin (200 mg once daily for 5 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rosiglitazone (4 mg single dose)
Number of subjects: 12
Study: 15684445

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39